LAPINO HOSPITAL STARTS TREATMENT OF PATIENTS WITH PNEUMONIA, INCLUDNG WITH CORONAVIRUS SYMPTOMS
|Download file (195 K)|
26 March 2020, Moscow. MD Medical Group Investments Plc (“MD Medical Group,” “MDMG,” the “Group” or the “Company” – LSE: MDMG), a leading Russian private healthcare provider, announces that it is starting to treat patients with symptoms of pneumonia, including patients with symptoms of coronavirus, in its clinical hospital Lapino.
In response to the needs of patients the management of the Company took the decision to start treating patients with symptoms of pneumonia, including patients with symptoms of coronavirus at its clinical hospital Lapino from 30 March 2020. The Lapino hospital has all the necessary medical facilities and professional competencies.
OBGYN patients, as well as the neonatology service patients, will temporarily receive medical help in the new MD Group Clinical Hospital (PMC) on Sevastopolsky prospect in Moscow which has the customary high standards of medical care characteristic of the Group. Obstetricians from the Lapino hospital will be relocated to the hospital to proceed with all delivery contracts. MD Group Clinical Hospital, which recently went through a major renovation, provides all the conditions for comfortable medical treatments.
Surgery, cardiology, traumatology and urology departments of the Lapino Clinical Hospital remain open to receive emergency patients. The paediatric department will continue to operate in normal mode. The Lapino hospital also has a department for pregnant women with signs of acute respiratory viral infections. Hospital work is organised in such a way that patients from different departments will not intersect within the walls of the hospital. The hospital has all the requirements for the autonomous functioning of all of these departments in full compliance with epidemiological standards.
For further information please contact:
MD Medical Group Investments Plc
Tel: +7 495 331 41 20
Tom Blackwell: +7 919 102 9064
Sergii Pershyn: +1 929 855 8188
About MD Medical Group
MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 42 modern healthcare facilities, including 6 hospitals and 36 out-patient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, Volgograd, Tula, Kazan, Vladivostok, Krasnodar and Rostov on Don
The Company’s shares have been listed on the London Stock Exchange (LSE ticker “MDMG”) in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements. No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.
2020 2019 2018 2017 2016 2015 2014 2013 2012